English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The incidence of colorectal cancer (CRC) is expected to increase by 80% in year 2035. Even though advantages in treatment of CRC have being made over the last decades, the outcome remains poor. Recently, several inflammatory markers including pretreatment neutrophil to lymphocyte ratio (NLR), have being used as prognostic factors, since host inflammatory response to cancer is believed to determine disease progression.  The aim of this study is to evaluate the prognostic significance of pretreatment NLR, in terms of overall survival (OS), 5-year survival, disease-free survival (DFS) and recurrence, in CRC patients who underwent curative resection.    Methods  We retrospectively reviewed 296 patients, who were submitted to elective surgery as first therapeutic option in curative intent, between January 2010 and December 2015. Pretreatment NLR, as well as demographics, clinical, histopathologic, and laboratory data were analyzed. Univariate and multivariate analyses were conducted to identify prognostic factors associated with OS, 5-year survival, DFS and recurrence.    Results  The cutoff point of NLR was calculated with Kaplan-Meier curves and log-rank test to 4.7. Univariate and multivariate analyses disclosed elevated NLR as a significant dismal prognostic factor for DFS (HR 1.88; 95% CI 1.01–3.52;  p  = 0.048), 5-year survival (HR 2.14; 95% CI 1.12–4.10;  p  = 0.021) and OS (HR 2.11; 95% CI 1.11–4.03;  p  = 0.023). In a subgroup analysis, in patients with stage II CRC, NLR &gt; 4.7 was a stronger poor predictor for DFS (HR 2.76; 95% CI 1.07–7.13;  p  = 0.036), 5-year survival (HR 3.84; 95% CI 1.39–10.63;  p  = 0.01) and OS (HR 3.62; 95% CI 1.33–4.82;  p  = 0.012). After adjusting stage for gender, age, location of the primary tumor, differentiation, as well as the presence of perineural, vascular, and lymphovascular invasion, the significance of NLR &gt; 4.7 became more prominent for DFS (HR 2.85; 95% CI 1.21–6.73;  p  = 0.0176), 5-year survival (HR 4.06; 95% CI 1.66–9.93;  p  = 0.002) and OS (HR 4.07; 95% CI 1.69–9.91;  p  = 0.002) in stage II patients.    Conclusion  Pretreatment NLR &gt; 4.7 is a poor prognostic factor for DFS, 5-year survival and OS in CRC patients undergoing curative resection. The dismal prognostic effect of NRL is magnified in Stage II CRC patients.

Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients